Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (DFPH) Gross Margin (2021 - 2025)

Historic Gross Margin for Oncology Institute (DFPH) over the last 5 years, with Q3 2025 value amounting to 13.85%.

  • Oncology Institute's Gross Margin fell 5300.0% to 13.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 67.69%, marking a year-over-year increase of 283600.0%. This contributed to the annual value of 52.5% for FY2024, which is 83300.0% up from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Gross Margin is 13.85%, which was down 5300.0% from 57.3% recorded in Q2 2025.
  • Oncology Institute's 5-year Gross Margin high stood at 166.73% for Q4 2024, and its period low was 13.85% during Q3 2025.
  • For the 5-year period, Oncology Institute's Gross Margin averaged around 51.36%, with its median value being 47.71% (2021).
  • Examining YoY changes over the last 5 years, Oncology Institute's Gross Margin showed a top increase of 1231000bps in 2024 and a maximum decrease of -308100bps in 2024.
  • Oncology Institute's Gross Margin (Quarter) stood at 47.71% in 2021, then dropped by -3bps to 46.26% in 2022, then dropped by -6bps to 43.62% in 2023, then skyrocketed by 282bps to 166.73% in 2024, then plummeted by -92bps to 13.85% in 2025.
  • Its Gross Margin was 13.85% in Q3 2025, compared to 57.3% in Q2 2025 and 54.91% in Q1 2025.